EcoDrugPlus

Tyrosine-Protein Kinase Jak2

Ensembl ID : ENSELUG00000015198
Gene Symbol: LOC105014676
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo

Ensembl ID : ENSELUG00000021295
Gene Symbol: LOC105027024
2 Cross references
182 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSELUG00000011897
Gene Symbol: LOC105017549
4 Cross references
300 Possible Orthologues:

Uncharacterized Loc105031171

Ensembl ID : ENSELUG00000010769
Gene Symbol: LOC105031171
2 Cross references
194 Possible Orthologues:

Utrophin

Ensembl ID : ENSELUG00000015837
Gene Symbol: UTRN
1 Cross references
254 Possible Orthologues:

Vascular Endothelial Growth Factor A-A

Ensembl ID : ENSELUG00000005205
Gene Symbol: LOC105017629
3 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor A-A

Ensembl ID : ENSELUG00000022721
Gene Symbol: LOC105006584
3 Cross references
181 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSELUG00000018144
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSELUG00000012103
Gene Symbol: LOC105024800
3 Cross references
394 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSELUG00000004329
Gene Symbol: LOC105007720
3 Cross references
191 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4

Ensembl ID : ENSELUG00000015287
Gene Symbol: LOC105026314
3 Cross references
203 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSELUG00000032838
Gene Symbol: LOC105010309
2 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).